Last update 24 Mar 2025

iNeo-Vac-R01

Overview

Basic Info

Drug Type
Therapeutic vaccine, mRNA vaccine
Synonyms
iNeo-Vac-R01
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease
Active Indication
Metastatic Pancreatic CancerPancreatic carcinoma non-resectablePancreatic Ductal Adenocarcinoma
Inactive Indication-
Originator Organization
Hangzhou New Anjin Biotechnology Co., LtdHangzhou New Anjin Biotechnology Co., Ltd
Active Organization
Hangzhou New Anjin Biotechnology Co., LtdHangzhou New Anjin Biotechnology Co., Ltd
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with iNeo-Vac-R01
NCT06888674
/ Not yet recruitingPhase 1/2IIT
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy Combined with PD-1 Antibody and Chemotherapy As Adjuvant Treatment for Postoperative Pancreatic Cancer.
NCT06888648
/ Not yet recruitingPhase 1/2IIT
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy in Combination with PD-1 Antibody and Chemotherapy for Advanced Pancreatic Cancer.
NCT06019702
/ RecruitingPhase 1IIT
A Clinical Study to Assess the Safety, Feasibility, and Efficacy of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
100 Clinical Results associated with iNeo-Vac-R01
Login to view more data
100 Translational Medicine associated with iNeo-Vac-R01
Login to view more data
100 Patents (Medical) associated with iNeo-Vac-R01
Login to view more data
100 Deals associated with iNeo-Vac-R01
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic CancerPhase 2
China
Hangzhou New Anjin Biotechnology Co., LtdHangzhou New Anjin Biotechnology Co., Ltd
01 Apr 2025
Pancreatic carcinoma non-resectablePhase 2
China
Hangzhou New Anjin Biotechnology Co., LtdHangzhou New Anjin Biotechnology Co., Ltd
01 Apr 2025
Pancreatic Ductal AdenocarcinomaPhase 2
China
Hangzhou New Anjin Biotechnology Co., LtdHangzhou New Anjin Biotechnology Co., Ltd
01 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free